Clinical Studies Show Long-Term Benefits Of Teva's Copaxone

Generic drugmaker Teva has shown that its innovative multiple sclerosis (MS) drug Copaxone (glatiramer acetate) causes a significant reduction in disease progression over a 15 year period. The news bodes well for Teva, both for its Copaxone sales and its research and development (R&D) division.

To read the full article, please choose one of the following options: